YTHDF2 and hepatocellular carcinoma: Among these prognosis-related m6A regulators, a number of previous studies have indicated that YTHDF2 is primarily involved in the malignant progression of pancreatic cancer, hepatocellular carcinoma, and acute myeloid leukemia (Chen et al., 2017; Paris et al., 2019; Zhong et al., 2019).